Document Detail


Meaning of low-density lipoprotein-apheresis for hypercholesterolemic patients at high risk for recurrence of coronary heart disease.
MedLine Citation:
PMID:  12423532     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The goal of cholesterol-lowering therapy in hypercholesterolemic patients at high risk for recurrence of coronary heart disease (CHD) is the prevention of acute coronary syndrome by stabilization of coronary atheromatous plaque. We often encounter patients in whom it is difficult to maintain the serum cholesterol level at a desirable level with dietary therapy and drug treatment, despite the development and use of statins. For secondary prevention in patients who are at high risk for the recurrence of CHD and whose cholesterol level cannot be controlled by drugs alone, low-density lipoprotein (LDL)-apheresis therapy, which involves removal of LDL through extracorporeal circulation, is now available. Many reports concerning improvement of vascular endothelial function, improvement of myocardial ischemia, regression of coronary atherosclerotic lesions, stabilization of coronary plaque, and reduction in the incidence of cardiac events as a result of LDL-apheresis treatment have been published in various countries. We believe that LDL-apheresis should be performed on hypercholesterolemic patients with existing CHD for whom diet and maximum cholesterol-lowering drug therapies have been ineffective or not tolerated and whose LDL cholesterol level is 160 mg/dL or higher.
Authors:
Nobuhiko Koga
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis     Volume:  6     ISSN:  1091-6660     ISO Abbreviation:  Ther Apher     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-11-08     Completed Date:  2003-01-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9706703     Medline TA:  Ther Apher     Country:  United States    
Other Details:
Languages:  eng     Pagination:  372-80     Citation Subset:  IM    
Affiliation:
Shin-Koga Hospital, Kurume, Japan. akikokhp@kureme.ktarn.or.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Component Removal*
Cholesterol, LDL / blood*
Coronary Artery Disease / blood,  therapy
Coronary Disease / blood,  etiology,  physiopathology,  prevention & control*
Endothelium, Vascular / physiopathology
Humans
Hypercholesterolemia / complications,  physiopathology,  therapy*
Myocardial Ischemia / therapy
Recurrence / prevention & control
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cholesterol, LDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprot...
Next Document:  First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recomme...